Neuron23 Stock
HealthTechLooking to sell Neuron23 stock or options?
Neuron23 develops an AI-driven drug discovery model focused on genetically defined neurological and immunological diseases. Using cutting-edge human genetics and their advanced AI-based drug discovery and biomarker platforms, Neuron23 aims to create therapeutics for severe diseases. This approach provides patients with genetic disorders access to improved medications.
Investors Include:
Chimera Capital, HBM Partners, HBM Healthcare Investments, Acorn Bioventures, Redmile Group, Origenis, Surveyor Capital, SoftBank Investment Advisers, Kleiner Perkins, Westlake Village BioPartners, Citadel Enterprise Americas, Perceptive Advisors, Cowen Healthcare Investments.